Published Paper Details:

Polycystic kidney disease (PKD) is an autosomal dominant disorder. It is a multisystem and progressive disease with cysts formation and kidney enlargement along with other organ involvement (e.g., liver, pancreas, spleen). Cystic kidneys are common causes of end-stage renal disease, both in children and in adults. In the adult population, it is the most frequent genetic cause of renal failure, with 6% to 8% of patients on dialysis in the US. By the age of 60 years, 50% of them need renal replacement therapy. Cysts may be detected in childhood or in utero, but clinical manifestations appear in the third or fourth decade of life. Enlarging cysts destroy the structure of nephrons, ultimately resulting in the loss of renal function. Eventually, ADPKD develops into end-stage renal disease. Currently, there is no effective drug therapy that can be safely used clinically. The conventional approach of management includes dialysis and renal transplantation, which are not affordable by Indian population mainly due to economic reasons. Therefore, exploration of a safe and alternative therapy is needed, which proves to be helpful in reducing the requirement of dialysis and in postponing the renal transplantation. It is a case of Polycystic kidney disease (PKD) which is correlated with Mutravaha Stotodushtijanya Vyadhi. A patient 46 year old presented in the OPD with Complaints of loss of weight, loss of Appetite, fatigue and also brought the RFT report which showed high creatinine, and high blood urea. After clinical examination, she was treated with oral medication for 3 months. She had relief in symptoms and also improvement in RFT reports.